Dihexa
Dihexa (PNB-0408)
Dihexa is a small molecule peptide derived from angiotensin IV. It potentiates hepatocyte growth factor (HGF) binding to its receptor MET with extraordinary affinity — approximately a million-fold more potent than BDNF at inducing new synapse formation. Research by Washington State University demonstrated dramatic cognitive rescue in Alzheimer's disease rat models, positioning Dihexa as a potential breakthrough for neurodegeneration.
Mechanism of Action
Dihexa binds to and potentiates the HGF/MET signalling axis. HGF-MET signalling drives synaptogenesis — the formation of new neural connections. By dramatically amplifying this pathway, Dihexa promotes dendritic spine density and synaptic plasticity in a way that exceeds known neurotrophic factors by orders of magnitude.
Unlike BDNF (which cannot cross the blood-brain barrier), Dihexa is a small lipophilic molecule with excellent CNS penetration orally and transdermally. This practical advantage combined with its extraordinary potency makes it a compelling cognitive enhancement research candidate.
Animal studies demonstrated that Dihexa-treated aged rats with cognitive decline performed at levels comparable to young controls on spatial memory tasks — with effects persisting weeks after cessation, suggesting lasting synaptic changes rather than transient pharmacological effects.
Research Evidence
Dihexa research is primarily from Washington State University's McCoy group. Dramatic findings in animal models have generated interest, but human clinical trials are not yet published. Anecdotal reports from users are broadly positive for cognitive enhancement.
Dihexa Overcomes Cognitive Impairment in Alzheimer's-Like Rodent Models
Dihexa potentiated HGF signalling ~1 million-fold relative to BDNF and completely restored spatial memory and social learning deficits in aged and scopolamine-impaired rats — with effects lasting 2+ weeks post-treatment.
Typical Research Protocol
Dihexa is active orally and transdermally, making it one of the most convenient cognitive peptides to use. Transdermal application (dissolved in DMSO or a cream) allows flexible dosing. No established optimal human dose.
Safety Profile
Reported Side Effects
- Overstimulation (anxiety, irritability at high doses)
- Headache
- Insomnia if taken late in day
Contraindications
- Active cancer (HGF/MET is a tumour growth pathway — significant theoretical concern)
- Personal/family history of certain cancers (MET-driven tumours)
- Pregnancy
Common Research Stacks
Frequently Asked Questions
Is Dihexa safe for long-term use?
Human long-term safety data is absent. The most significant theoretical concern is HGF/MET pathway amplification in the context of malignancy — MET is a well-established oncogene. Anyone with a personal or family history of MET-driven cancers (gastric, lung, kidney) should avoid Dihexa. For otherwise healthy individuals, short-cycle use with monitoring is the conservative approach.
How potent is Dihexa compared to other nootropics?
Dihexa is reported to be approximately 1 million-fold more potent than BDNF at inducing synaptogenesis in the HGF/MET assay used by its discoverers. In animal cognitive rescue experiments, it outperformed BDNF in both potency and duration of effect. This extraordinary in-vitro potency has made it one of the most discussed compounds in nootropic research circles, though human clinical data remains absent.
What is the best way to administer Dihexa?
Dihexa is active orally due to its small size and lipophilicity. Oral capsules (dissolved in DMSO-containing solutions or fat-soluble carriers) and transdermal cream applications are the most common research approaches. Transdermal delivery via DMSO vehicle may improve CNS penetration. Some researchers prefer SC injection for precise dosing, though oral/transdermal is more practical for most research contexts.
How long do Dihexa's effects persist after stopping?
This is one of Dihexa's most interesting characteristics. In animal studies, cognitive improvements persisted for 2–4 weeks after the last dose — substantially longer than the compound itself persists in the body. This persistence suggests Dihexa drives lasting structural synaptic changes (synaptogenesis) rather than simply modulating neurotransmitter levels. Human persistence data is not available.
Can Dihexa be combined with Semax or other BDNF-stimulating peptides?
Yes — Dihexa (HGF/MET synaptogenesis) and Semax (BDNF upregulation via TrkB) act through different neuroplasticity pathways, making combination theoretically synergistic. Both promote neural connectivity but via distinct growth factor systems. The combination is used by some cognitive researchers seeking comprehensive neuroplasticity support. No safety concerns specific to the combination have been identified.
Key Research References
- McCoy AT et al. (2013). Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther.
- Wright JW et al. (2013). Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning and memory. Neurosci Biobehav Rev.
Explore more Cognitive research compounds
Browse Cognitive →